Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5284 Target Snapshot

Calcium/calmodulin-dependent protein kinase kinase 2 · SINGLE PROTEIN · Homo sapiens

984Compounds
310Assays
15Approved Drugs
607.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q96RR4. Use UniProt Q96RR4 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q96RR4 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Calcium/calmodulin-dependent protein kinase kinase 2 as ChEMBL target CHEMBL5284, mapped to UniProt Q96RR4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Calcium/calmodulin-dependent protein kinase kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5284
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96RR4
Calcium/calmodulin-dependent protein kinase kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Calcium/calmodulin-dependent protein kinase kinase 2 is the right protein anchor across sources, using UniProt Q96RR4 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCalcium/calmodulin-dependent protein kinase kinase 2
UniProt AccessionQ96RR4
Component TypeProtein
Sequence Length588 aa

Calcium/calmodulin-dependent protein kinase kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Calcium/calmodulin-dependent protein kinase kinase 2, mapped to UniProt Q96RR4. Sequence length is 588 aa.

Mapped IDQ96RR4
Review nameCalcium/calmodulin-dependent protein kinase kinase 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

15
Approved
7
Phase III
9
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50160.0
KI47.0
EC5012.0
KD388.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 10.3 Kd 0.05 Preclinical
CHEMBL1980995 9.7 Ki 0.1995 Preclinical
CHEMBL458997 8.9 Ki 1.259 Preclinical
CHEMBL1993661 8.9 Ki 1.259 Preclinical
CHEMBL5421767 8.85 IC50 1.4 Preclinical
CHEMBL4126095 8.8 IC50 1.585 Preclinical
CHEMBL416056 8.74 Ki 1.8 Preclinical
CHEMBL4465866 8.7 Kd 2.0 Preclinical
CHEMBL4128577 8.7 IC50 1.995 Preclinical
CHEMBL4129590 8.7 IC50 1.995 Preclinical
Distribution

pChEMBL Value Distribution

17
5.0
47
5.5
33
6.0
40
6.5
28
7.0
41
7.5
14
8.0
11
8.5
0
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
Assay Landscape

Assay Landscape

310
Total Assays
189
Tested Compounds
2
Assay Types
Binding — 309 assays, 189 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 228 127 6.9
cell-based format 34 36 6.8
assay format 32 1 6.1
subcellular format 15 25 5.8
Functional — 1 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 11 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine